When a meta-analysis was performed on 19 small randomized trials and the first three cardiovascular outcome trials with DPP-4 inhibitors that were published, a non-significant trend toward protection against stroke was found, but this trend disappeared when only the cardiovascular outcome trials were introduced into another pooled analysis [45]. This evidence concerns the gene DPP4 and Stroke.